Bethany Sensenig joins Alpha Cognition (NASDAQ: ACOG) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors effective April 15, 2026. She brings senior finance and operations experience from roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and a 13-year career at Biogen with P&L responsibility over about $1 billion in annual revenue across 30 countries.
As a non-employee director, she will be compensated under the company’s standard policy and received an initial equity grant of 5,489 restricted stock units and 6,991 stock options, with an exercise price of $6.65 per share. Both the RSUs and options vest one year after the grant date. The company states there are no arrangements, family relationships, or related-party transactions linked to her appointment.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director RSU grant: 5,489 restricted stock units
Director stock options: 6,991 stock options
Option exercise price: $6.65 per share
+4 more
7 metrics
Director RSU grant
5,489 restricted stock units
Initial equity grant to Bethany Sensenig upon board appointment
Director stock options
6,991 stock options
Initial option grant to Bethany Sensenig upon board appointment
Option exercise price
$6.65 per share
Exercise price of stock options granted to Bethany Sensenig
P&L responsibility
$1 billion annual revenue
P&L accountability at Biogen across about 30 countries
Radius Health tenure
May 2024 to April 2026
CFO and Head of Operations at Radius Health
9 Meters Biopharma tenure
Jan 2022 to July 2023
CFO and Interim CEO at 9 Meters Biopharma
Minovia Therapeutics tenure
June 2019 to Jan 2022
CFO and Head of U.S. Operations at Minovia Therapeutics
Key Terms
restricted stock units, stock options, exercise price, non-employee director compensation policy, +1 more
5 terms
restricted stock units financial
"in connection with her appointment, Ms. Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"in connection with her appointment, Ms. Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"The stock options have an exercise price of $6.65 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
non-employee director compensation policy financial
"Ms. Sensenig will receive compensation in accordance with the Company’s previously disclosed non-employee director compensation policy."
Regulation S-K regulatory
"the type required to be disclosed pursuant to Item 404(a) of Regulation S-K, and no such transaction is currently contemplated."
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
FAQ
What did Alpha Cognition (ACOG) announce about its board of directors?
Alpha Cognition appointed Bethany Sensenig as a new director effective April 15, 2026. She is an experienced biotechnology finance executive who previously held senior roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and Biogen, adding significant financial and operational expertise to the board.
What equity awards did Bethany Sensenig receive from Alpha Cognition (ACOG)?
Bethany Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options from Alpha Cognition. The stock options carry an exercise price of $6.65 per share, and both the restricted stock units and options vest one year after the date of grant.
What is Bethany Sensenig’s background relevant to Alpha Cognition (ACOG)?
Bethany Sensenig most recently served as Chief Financial Officer and Head of Operations at Radius Health. She previously was CFO and Interim CEO at 9 Meters Biopharma, CFO and Head of U.S. Operations at Minovia Therapeutics, and spent 13 years at Biogen in progressively senior finance roles.
Does Bethany Sensenig have other board roles outside Alpha Cognition (ACOG)?
Yes. Bethany Sensenig also serves on the boards of Supernus Pharmaceuticals (NASDAQ: SUPN) and KalVista Pharmaceuticals (NASDAQ: KALV). These external directorships reflect her broader industry involvement and experience in the biopharmaceutical sector, complementing her executive finance and operations background.
How will Alpha Cognition (ACOG) compensate Bethany Sensenig as a director?
Bethany Sensenig will receive compensation consistent with Alpha Cognition’s existing non-employee director compensation policy. In connection with her appointment, she received an annual equity grant consisting of 5,489 restricted stock units and 6,991 stock options, all vesting one year after the grant date.